ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 157.7 DKK -2.23%
Market Cap: 34.9B DKK
Have any thoughts about
ALK-Abello A/S?
Write Note

Operating Margin
ALK-Abello A/S

20.1%
Current
12%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
20.1%
=
Operating Profit
1.1B
/
Revenue
5.4B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DK
ALK-Abello A/S
CSE:ALK B
34.8B DKK
20%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.9T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
28%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
34%
CH
Roche Holding AG
SIX:ROG
197B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
160.1B GBP
21%
CH
Novartis AG
SIX:NOVN
169.8B CHF
31%
US
Pfizer Inc
NYSE:PFE
149.4B USD
22%
Country DK
Market Cap 34.8B DKK
Operating Margin
20%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 729.3B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.9T DKK
Operating Margin
44%
Country US
Market Cap 347.8B USD
Operating Margin
28%
Country US
Market Cap 248.3B USD
Operating Margin
34%
Country CH
Market Cap 197B CHF
Operating Margin
32%
Country UK
Market Cap 160.1B GBP
Operating Margin
21%
Country CH
Market Cap 169.8B CHF
Operating Margin
31%
Country US
Market Cap 149.4B USD
Operating Margin
22%
No Stocks Found

ALK-Abello A/S
Glance View

Market Cap
34.9B DKK
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

ALK B Intrinsic Value
153.16 DKK
Overvaluation 3%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
20.1%
=
Operating Profit
1.1B
/
Revenue
5.4B
What is the Operating Margin of ALK-Abello A/S?

Based on ALK-Abello A/S's most recent financial statements, the company has Operating Margin of 20.1%.